Lymphoma & Leukaemia Watch 50 - Transplantation for Hodgkin lymphoma

Dr Shafqat Inam FRACP FRCPA

ASH Lymphoma & Leukaemia Highlights 2025

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Lymphoma & Leukaemia Watch 49 - Some important studies of brentuximab vedotin for Hodgkin Lymphoma

Professor H. Miles Prince MBBS (Hons), MD, FRACP, FRCPA, AFRACMA, MACD

Lymphoma & Leukaemia Watch 47 - Large B-cell lymphoma EHA clinical practice guidelines

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Lymphoma & Leukaemia Watch 46 - Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment and follow-up

Professor H. Miles Prince MBBS (Hons), MD, FRACP, FRCPA, AFRACMA, MACD

Lymphoma & Leukaemia Watch 45 - MRD in CLL... what is it and does it matter?

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Associate Professor Shaun Fleming discusses CAR T-cell treatment for relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL)

Associate Professor Shaun Fleming MBBS(Hons) FRACP FRCPA

Head of Myeloid Diseases Service, Clinical Haematology, Alfred Hospital

Conjoint Associate Professor, Australian Centre for Blood Diseases, Monash University

Lymphoma & Leukaemia Watch 44 - Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium study

Professor H. Miles Prince MBBS (Hons), MD, FRACP, FRCPA, AFRACMA, MACD

Lymphoma & Leukaemia Watch 43 - Follicular lymphoma into the future

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

ESMO Clinical practice guideline interim update on the new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia

Professor Arnon Kater
Haematologist, Amsterdam University Medical Center

BSH Highlights 2025

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Lymphoma & Leukaemia Watch 42 - Odronextamab for DLBCL

Professor H. Miles Prince MBBS (Hons), MD, FRACP, FRCPA, AFRACMA, MACD

Professor Michael Dickinson discusses CAR T-Cell Therapy: Axicabtagene Ciloleucel for Second-Line Treatment of Relapsed or Refractory Large B-Cell Lymphoma

Professor Michael Dickinson MBBS, D Med Sc, FRACP, FRCPA

Lymphoma & Leukaemia Watch 41 - Novel approaches in T cell lymphoma

Dr Hannah Hsu BMedSci, MBBS, FRACP, FRCPA

Lymphoma & Leukaemia Watch 40 - AMPLIFYing CLL

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

ASH Highlights 2024 focus on Lymphoma & Leukaemia

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Lymphoma & Leukaemia Watch 39 - AN + AD for advanced stage Hodgkin Lymphoma

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Blood Highlights 2024 - Focus Lymphoma & Leukaemia

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Lymphoma & Leukaemia Watch 38 - Mantle cell lymphoma into the future

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Lymphoma & Leukaemia Watch 37 - Treatment of minimal residual disease in acute myeloid leukaemia

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Professor Michael Dickinson discusses CAR T Cell Treatment for Relapsed or Refractory Mantle Cell Lymphoma

Professor Michael Dickinson MBBS, D Med Sc, FRACP, FRCPA

Lymphoma & Leukaemia Watch 36 - Early stage follicular lymphoma

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Lymphoma & Leukaemia Watch 35 - Deciding on allograft in NPM1 AML

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Lymphoma & Leukaemia Watch 34 - Asciminib in chronic myeloid leukaemia

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Lymphoma & Leukaemia Watch 33 - 2 new treatments for T cell lymphomas

Professor H. Miles Prince MBBS (Hons), MD, FRACP, FRCPA, AFRACMA, MACD

Lymphoma & Leukaemia Watch 32 - Luspatercept vs epoetin alfa for treatment of anaemia in low risk MDS

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

ASH Highlights 2023

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Lymphoma & Leukaemia Watch 30 - Allograft prolongs survival in TP53 mutated MDS

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Lymphoma & Leukaemia Watch 29 - Menin inhibitor revumenib in refractory acute leukaemia

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Lymphoma & Leukaemia Watch 27 - Zanubrutinib vs Ibrutinib in relapsed/refractory Chronic Lymphocytic Leukaemia

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Lymphoma & Leukaemia Watch 25 - Bispecific Antibodies in B-Cell Lymphoma

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Lymphoma & Leukaemia Watch 23 - Ph+ ALL; Decision making regarding allograft in CR1

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Lymphoma & Leukaemia Watch 22 - Updates in diffuse large B cell Lymphoma

Dr Shafqat Inam MBBS MMed FRACP FRCPA

Lymphoma & Leukaemia Watch 21 - Updates in peripheral T cell lymphoma

Dr Shafqat Inam MBBS MMed FRACP FRCPA

Lymphoma & Leukaemia Watch 20 - POLARIX Study - A New Standard of Care in DLBCL?

Professor Constantine Tam MBBS (Hons) MD FRACP FRCPA

Lymphoma & Leukaemia Watch 18 - A Randomized Phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Lymphoma & Leukaemia Watch 17- Development of Second Generation BTKi in the Treatment of Lymphoid Cancers Part 2

Professor Constantine Tam MBBS (Hons) MD FRACP FRCPA

Lymphoma & Leukaemia Watch 15 - SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab in Patients with Treatment-Naive CLL/SLL

Professor Constantine Tam MBBS (Hons) MD FRACP FRCPA

Lymphoma & Leukaemia Watch 14 - Recent local and international studies assessing pediatric ALL therapy adults <40y

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Lymphoma & Leukaemia Watch 12 - Advanced Stage Hodgkin Lymphoma: a case based approach

Professor Mark Hertzberg MBBS PhD FRACP FRCPA

Lymphoma & Leukaemia Watch 10 - New evidence to aid decision making in the treatment of older patients with AML (Part 1)

Dr Bartlomiej Getta MBBS (HONS 1) (UNSW) GRAD CERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Lymphoma & Leukaemia Watch 7 - Updates in secondary CNS and limited stage diffuse large B cell Lymphoma

Dr Pietro Di Ciaccio BA LLB (Hons) MBBS FRACP FRCPA

Lymphoma & Leukaemia Watch 6 - Two updates in Burkitt & HGBCL

Dr Pietro Di Ciaccio BA LLB (Hons) MBBS FRACP FRCPA

Lymphoma & Leukaemia Watch 5 - Polatuzumab Vedotin & Relapsed/Refractory Diffuse Large B-cell Lymphoma

Professor Mark Hertzberg MBBS PhD FRACP FRCPA

Lymphoma & Leukaemia Watch 4 - Relapsed, Refractory Hodgkin Lymphoma-Update

Professor Mark Hertzberg MBBS PhD FRACP FRCPA

Lymphoma & Leukaemia Watch 3 - Follicular Lymphoma Treatment of Advanced Stage High Tumour Burden-A Recent Update

Prof. Mark Hertzberg MBBS PhD FRACP FRCPA

Lymphoma & Leukaemia Watch 2 - Hodgkin Lymphoma: two recent trial updates in first line therapy

Prof. Mark Hertzberg MBBS PhD FRACP FRCPA

Lymphoma & Leukaemia Watch 1 - Diffuse Large B-cell Lymphoma: two recent updates

Professor Mark Hertzberg MBBS PhD FRACP FRCPA

Treating CLL with novel therapies

Professor Peter Hillmen

Lymphoma & Leukaemia Watch 50 - Transplantation for Hodgkin lymphoma

ASH Lymphoma & Leukaemia Highlights 2025

Lymphoma & Leukaemia Watch 49 - Some important studies of brentuximab vedotin for Hodgkin Lymphoma

Lymphoma & Leukaemia Watch 47 - Large B-cell lymphoma EHA clinical practice guidelines

Lymphoma & Leukaemia Watch 46 - Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment and follow-up

Lymphoma & Leukaemia Watch 45 - MRD in CLL... what is it and does it matter?

Associate Professor Shaun Fleming discusses CAR T-cell treatment for relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL)

Lymphoma & Leukaemia Watch 44 - Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium study

Lymphoma & Leukaemia Watch 43 - Follicular lymphoma into the future

ESMO Clinical practice guideline interim update on the new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia

BSH Highlights 2025

Lymphoma & Leukaemia Watch 42 - Odronextamab for DLBCL

Professor Michael Dickinson discusses CAR T-Cell Therapy: Axicabtagene Ciloleucel for Second-Line Treatment of Relapsed or Refractory Large B-Cell Lymphoma

Lymphoma & Leukaemia Watch 41 - Novel approaches in T cell lymphoma

Lymphoma & Leukaemia Watch 40 - AMPLIFYing CLL

ASH Highlights 2024 focus on Lymphoma & Leukaemia

Lymphoma & Leukaemia Watch 39 - AN + AD for advanced stage Hodgkin Lymphoma

Blood Highlights 2024 - Focus Lymphoma & Leukaemia

Lymphoma & Leukaemia Watch 38 - Mantle cell lymphoma into the future

Lymphoma & Leukaemia Watch 37 - Treatment of minimal residual disease in acute myeloid leukaemia

Professor Michael Dickinson discusses CAR T Cell Treatment for Relapsed or Refractory Mantle Cell Lymphoma

Lymphoma & Leukaemia Watch 36 - Early stage follicular lymphoma

Lymphoma & Leukaemia Watch 35 - Deciding on allograft in NPM1 AML

Lymphoma & Leukaemia Watch 34 - Asciminib in chronic myeloid leukaemia

Lymphoma & Leukaemia Watch 33 - 2 new treatments for T cell lymphomas

Lymphoma & Leukaemia Watch 32 - Luspatercept vs epoetin alfa for treatment of anaemia in low risk MDS

ASH Highlights 2023

Lymphoma & Leukaemia Watch 30 - Allograft prolongs survival in TP53 mutated MDS

Lymphoma & Leukaemia Watch 29 - Menin inhibitor revumenib in refractory acute leukaemia

Lymphoma & Leukaemia Watch 27 - Zanubrutinib vs Ibrutinib in relapsed/refractory Chronic Lymphocytic Leukaemia

Lymphoma & Leukaemia Watch 25 - Bispecific Antibodies in B-Cell Lymphoma

Lymphoma & Leukaemia Watch 23 - Ph+ ALL; Decision making regarding allograft in CR1

Lymphoma & Leukaemia Watch 22 - Updates in diffuse large B cell Lymphoma

Lymphoma & Leukaemia Watch 21 - Updates in peripheral T cell lymphoma

Lymphoma & Leukaemia Watch 20 - POLARIX Study - A New Standard of Care in DLBCL?

Lymphoma & Leukaemia Watch 18 - A Randomized Phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Lymphoma & Leukaemia Watch 17- Development of Second Generation BTKi in the Treatment of Lymphoid Cancers Part 2

Lymphoma & Leukaemia Watch 15 - SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab in Patients with Treatment-Naive CLL/SLL

Lymphoma & Leukaemia Watch 14 - Recent local and international studies assessing pediatric ALL therapy adults <40y

Lymphoma & Leukaemia Watch 12 - Advanced Stage Hodgkin Lymphoma: a case based approach

Lymphoma & Leukaemia Watch 10 - New evidence to aid decision making in the treatment of older patients with AML (Part 1)

Lymphoma & Leukaemia Watch 7 - Updates in secondary CNS and limited stage diffuse large B cell Lymphoma

Lymphoma & Leukaemia Watch 6 - Two updates in Burkitt & HGBCL

Lymphoma & Leukaemia Watch 5 - Polatuzumab Vedotin & Relapsed/Refractory Diffuse Large B-cell Lymphoma

Lymphoma & Leukaemia Watch 4 - Relapsed, Refractory Hodgkin Lymphoma-Update

Lymphoma & Leukaemia Watch 3 - Follicular Lymphoma Treatment of Advanced Stage High Tumour Burden-A Recent Update

Lymphoma & Leukaemia Watch 2 - Hodgkin Lymphoma: two recent trial updates in first line therapy

Lymphoma & Leukaemia Watch 1 - Diffuse Large B-cell Lymphoma: two recent updates

Treating CLL with novel therapies

Get Free publications straight to your inbox.